A top-level international research team including researchers from the University of Eastern Finland has developed a new algorithm for the diagnostics of dementia. The algorithm is based on blood and cerebrospinal fluid biomarker measurements. These biomarkers can be used to aid setting of an exact diagnosis already in the early phases of dementia.
Using naturalistic driving data and machine learning techniques, researchers have developed highly accurate algorithms for detecting mild cognitive impairment and dementia in older drivers. Naturalistic driving data refer to data captured through in-vehicle recording devices or other technologies in the real-world setting. These data could be processed to measure driving exposure, space and performance in great detail.
Enhancing the brain's lymphatic system when administering immunotherapies may lead to better clinical outcomes for Alzheimer's disease patients, according to a new study in mice. Results published April 28 in Nature suggest that treatments such as the immunotherapies BAN2401 or aducanumab might be more effective when the brain's lymphatic system can better drain the amyloid-beta protein that accumulates in the brains of those living with Alzheimer's.
Researchers at Washington University School of Medicine in St. Louis have found that improving the function of the brain's drainage network, known as the meningeal lymphatics, can make certain experimental Alzheimer's therapies more effective in mice.
University of California, Irvine biologists have developed a new genetically engineered mouse model that, unlike its predecessors, is based on the most common form of Alzheimer's disease. The advance holds promise for making new strides against the neurodegenerative disease as cases continue to soar.
Despite the prevalence of Alzheimer's, there are still no treatments, in part because it has been challenging to study how the disease develops. Now, scientists at the Salk Institute have uncovered new insights into what goes awry during Alzheimer's by growing neurons that resemble--more accurately than ever before--brain cells in older patients. And like patients themselves, the afflicted neurons appear to lose their cellular identity.
Brain changes in people with Alzheimer's disease and in those with mild traumatic brain injuries (TBIs) have significant similarities.
As a potential framework for assessing an asymptomatic person's risk of developing dementia, the National Institute on Aging and the Alzheimer's Association have endorsed a research tool based on three biomarkers called the AT(N) framework--A, for amyloid, T for tau, and (N) for neurodegeneration or atrophy. However, a new study by researchers in Seattle suggests a subset of people classified by this approach as having the highest risk for dementia will not develop dementia in their lifetime.
Rising levels of dementia is putting pressure on residential aged care facilities, including in rural and regional centres where nursing homes and staff are already under pressure. Now a pilot program of personalised interventions, including residents' favourite songs, has been shown to make a big difference to dementia behaviours, drug use and carers' wellbeing.
New biomarkers for Alzheimer's disease are a priority area for researchers seeking to learn more about the disease and find possible methods of early diagnosis. Researchers at Karolinska Institutet in Sweden have now studied a new PET tracer that is an important diagnostic tool for the disease. The study on the tracer substance BU99008, which is published in Molecular Psychiatry, can play a key part in the early identification of signs of Alzheimer's disease.